Smoking out reproductive hormone actions in lung cancer

Molecular Cancer Research

Volumn 12, Issue 1, 2014, Pages 24-31

  Siegfried, Jill M ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AROMATASE; ESTRADIOL; ESTROGEN RECEPTOR; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; ESTRONE; FULVESTRANT; PROGESTERONE RECEPTOR; TESTOSTERONE;

CLINICAL TRIAL (TOPIC); ESTROGEN SYNTHESIS; HUMAN; LUNG CANCER; LUNG TUMOR; PRECURSOR; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION;

AROMATASE; CARCINOMA, NON-SMALL-CELL LUNG; ESTRADIOL; ESTROGEN ANTAGONISTS; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; FEMALE; HUMANS; LUNG; LUNG NEOPLASMS; MALE; RECEPTOR, EPIDERMAL GROWTH FACTOR; SMOKING; TESTOSTERONE;

EID: 84893059167     PISSN: 15417786     EISSN: 15573125     Source Type: Journal    
DOI: 10.1158/1541-7786.MCR-13-0580     Document Type: Review

References (80)

1. Mosselman S, Polman J, Dijkema R. ER beta: identification and characterization of a novel human estrogen receptor. FEBS Lett 1996;392:49-53.
2. Lin AHY, Li RWS, Ho EYW, Leung GPH, Leung SWS, Vanhoutte PM, et al. Differential ligand binding affinities of human estrogen receptor-a isoforms. PLOS ONE 2013;8:e63199.
3. Leung YK, Mak P, Hassan S, Ho SM. Estrogen receptor (ER)-beta isoforms: a key to understanding ER-beta signaling. Proc Natl Acad Sci U S A 2006;103:13162-7.
4. Shaaban AM, Green AR, Karthik S, Alizadeh Y, Hughes TA, Harkins L, et al. Nuclear and cytoplasmic expression of ERbeta1, ERbeta2, and ERbeta5 identifies distinct prognostic outcome for breast cancer patients. Clin Cancer Res 2008;14:5228-35.
5. Brandenberger AW, Tee MK, Lee JY, Chao V, Jaffe RB. Tissue distribution of estrogen receptors alpha (ER-a) and beta (ER-b) mRNA in the midgestational human fetus. J Clin Endocrin Metab 1997;82: 3509-12.
6. Patrone C, Caael TN, Pettersson K, Piao YS, Cheng G, Ciana P, et al. Regulation of postnatal lung development and homeostasis by estrogen receptor b. Mol Cell Biol 2003;23:8542-52.
7. Morani A, Barros RP, Imamov O, Hultenby K, Arner A, Warner M, et al. Lung dysfunction causes systemic hypoxia in estrogen receptor beta knockout (ERbeta-/-) mice. Proc Natl Acad Sci U S A 2006;103:7165-9.
8. Benninghoff AD, Williams DE. The role of estrogen receptor b in transplacental cancer prevention by indole-3-carbinol. Cancer Prev Res 2013;6:339-48.
9. Chen Z, Zhang Y, Yang H, Jin M, Wang XW, Shen ZQ, et al. Estrogen promotes benzo[a]pyrene-induced lung carcinogenesis through exidative stress damage and cytochrome c-mediated caspase-3 activation pathways in female mile. Cancer Lett 2011;308:14-22.
10. Stabile LP, Davis AL, Gubish CT, Hopkins TM, Luketich JD, Christie N, et al. Human non-small cell lung tumors and cells derived from normal lung express both estrogen receptor alpha and beta and show biological responses to estrogen. Cancer Res 2002;62:2141-50.
11. Wu CT, Chang YL, Shih JY, Lee YC. The significance of estrogen receptor beta in 301 surgically treated non-small cell lung cancers. J Thorac Cardiovasc Surg 2005;130:979-86.
12. Schwartz AG, Prysak GM, Murphy V, Lonardo F, Pass H, Schwartz J, et al. Nuclear estrogen receptor beta in lung cancer: expression and survival differences by sex. Clin Cancer Res 2005;11:7280-7.
13. Kawai H, Ishii A, Washiya K, Konno T, Kon H, Yamaya C, et al. Combined overexpression of EGFR and estrogen receptor alpha correlates with a poor outcome in lung cancer. Anticancer Res 2005; 25:4693-8.
14. Skov BG, Fischer BM, Pappot H. Oestrogen receptor b over expression in males with non-small cell lung cancer is associated with better survival. Lung Cancer 2008;59:88-94.
15. Liu Z, Liao Y, Tang H, Chen G. The expression of estrogen receptors b2,5 identifies and is associated with prognosis in non-small cell lung cancer. Endocrine 2013;44:517-24.
16. Hershberger PA, Vasquez AC, Kanterewicz B, Land S, Siegfried JM, Nichols M. Regulation of endogenous gene expression in human nonsmall cell lung cancer cells by estrogen receptor ligands. Cancer Res 2005;65:1598-605.
17. Hershberger PA, Stabile LP, Kanterewicz B, Rothstein ME, Gubish CT, Land S, et al. Estrogen receptor beta (ERbeta) subtype-specific ligands increase transcription, p44/p42 mitogen activated protein kinase (MAPK) activation and growth in human non-small cell lung cancer cells. J Steroid Biochem Mol Biol 2009;116:102-9.
18. Mazieres J, Rouquette I, Lepage B, Milia J, Brouchet L, Guibert N, et al. Specificities of lung adenocarcinoma in women who have never smoked. J Thorac Oncol 2013;8:923-9.
19. Stabile LP, Dacic S, Land SR, Lenzner DE, Dhir R, Acquafondata M, et al. Combined analysis of estrogen receptor b-1 and progesterone receptor expression identifies lung cancer patients with poor outcome. Clin Cancer Res 2011;17:154-64.
20. Sethi S, Coti M, Lonardo F. Expression of estrogen receptor beta 1 but not estrogen receptor beta 2 or alpha is linked to worse prognosis in stage I adenocarcinoma, in women, in a large epidemiological cohort but not in a smaller, single hospital based series. United States and Canadian Academy of Pathology; 2010. Abstract 1843.
21. Navaratnam S, Skliris G, Qing G, Banerji S, Badiani K, Tu D, et al. Differential role of estrogen receptor beta in early versus metastatic non-small cell lung cancer. Horm Cancer 2012;3:93-100.
22. Zhang G, Yanamala N, Lathrop KL, Zhang L, Klein-Seetharaman J, Srinivas H. Ligand-independent antiapoptotic function of estrogen receptor-beta in lung cancer cells. Mol Endocrinol 2010;24: 1737-47.
23. Simoes DC, Psarra AM, Mauad T, Pantou I, Roussos C, Sekeris CE, et al. Glucocorticoid and estrogen receptors are reduced in mitochondria of lung epithelial cells in asthma. PLoS ONE 2012;7: e39183.
24. Blaustein JD. Steroid hormone receptors: long-and short-term integrators of the internal milieu and the external environment. Horm Metab Res 2012;44:563-8.
25. Lemmen JG, Arends RJ, van Boxtel AL, van der Saag PT, van der Burg B. Tissue-and time-dependent estrogen receptor activation in estrogen reporter mice. J Mol Endocrinol 2004;32:689-701.
26. Ciana P, DiLuccio G, Belcredito S, Pollio G, Vegeto E, Tatangelo L, et al. Engineering of a mouse for the in vivo profiling of estrogen receptor activity. Mol Endocrinol 2001;15:1104-13.
27. Kato S, Endoh H, Masuhiro Y, Kitamoto T, Uchiyama S, Sasaki H, et al. Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase. Science 1995;270:1491-4.
28. Marquez-Garban DC, Chen H-W, Fishbein MC, Goodglick L, Pietras RJ. Estrogen receptor signaling pathways in human non-small cell lung cancer. Steroids 2007;72:135-43.
29. Thomas P, Pang Y, Filardo EJ, Dong J. Identity of an estrogen membrane receptor coupled to a G protein in human breast cancer cells. Endocrinology 2005;146:624-32.
30. Jala VR, Radde BBN, Haribabu B, Klinge CM. Enhanced expression of G-protein coupled estrogen receptor (GPER/GPR30) in lung cancer. BMC Cancer 2012;12:624.
31. Kang L, Zhang X, Xie Y, Tu Y, Wang D, Liu Z, et al. Involvement of estrogen receptor variant ER-{alpha}36, Not GPR30, in nongenomic estrogen signaling. Mol Endocrinol 2010;24:709-21.
32. Pietras RJ, Marquez-Garban DC. Membrane-associated estrogen receptor signaling pathways in human cancers. Clin Cancer Res 2007; 13:4672-6.
33. Rajkumar T, Gullick WJ. The type I growth factor receptors in human breast cancer. Breast Cancer Res Treat 1994;29:3-9.
34. Rosell R, Bivona TG, Karachaliou N. Genetics and biomarkers in personalisation of lung cancer treatment. Lancet 2013;382:720-31.
35. Stabile LP, Lyker JS, Gubish CT, Zhang W, Grandis JR, Siegfried JM. Combined targeting of the estrogen receptor and the epidermal growth factor receptor in non-small cell lung cancer shows enhanced antiproliferative effects. Cancer Res 2005;65:1459-70.
36. Garon EB, Pietras RJ, Finn RS, Kamranpour N, Pitts S, Marquez-Garban DC, et al. Antiestrogen fulvestrant enhances the antiproliferative effects of epidermal growth factor receptor inhibitors in human non-small cell lung cancer. J Thorac Oncol 2013;8:270-8.
37. Siegfried JM, Gubish CT, Rothstein ME, Henry C, Stabile LP. Combining the multitargeted kinase inhibitor vandetanib with the antiestrogen fulvestrant enhances its antitumor effect in non-small cell lung cancer. J Thorac Oncol 2012;7:485-95.
38. Shen L, Li Z, Shen S, Niu X, Yu Y, Li Z, et al. The synergistic effect of EGFR tyrosine kinase inhibitor gefitinib in combination with aromatase inhibitor anastrozole in non-small cell lung cancer cell lines. Lung Cancer 2012;78:193-200.
39. Martel C, Melner MH, Gagné D, Simard J, Labrie F. Widespread tissue distribution of steroid sulfatase, 3 beta-hydroxysteroid dehydrogenase/ delta 5-delta 4 isomerase (3 beta-HSD), 17 beta-HSD 5 alphareductase and aromatase activities in the rhesus monkey. Mol Cell Endocrinol 1994;104:103-11.
40. Price T, Aitken J, Simpson ER. Relative expression of aromatase cytochrome P450 in human fetal tissues as determined by competitive polymerase chain reaction amplification. J Clin Endocrinol Metab 1992;74:879-83.
41. Niikawa H, Suzuki T, Miki Y, Suzuki S, Nagasaki S, Akahira J, et al. Intratumoral estrogens and estrogen receptors in human non-small cell lung carcinoma. Clin Cancer Res 2008;14:4417-26.
42. Xu X, Veenstra TD. Concentration of endogenous estrogens and estrogen metabolites in the NCI-60 human tumor cell lines. Gen Med 2012;4:31.
43. Weinberg OK, Marquez-Garban DC, Fishbein MC, Goodglick L, Garban HJ, Dubinett SM, et al. Aromatase inhibitors in human lung cancer therapy. Cancer Res 2005;65:11287-91.
44. Stabile LP, Rothstein ME, Cunningham DE, Land SR, Dacic S, Keohavong P, et al. Prevention of tobacco carcinogen-induced lung cancer in female mice using antiestrogens. Carcinogenesis 2012;33: 2181-9.
45. Coombes RC, Hall E, Gibson LJ, Paridaens R, Jassem J, Delozier T, et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 2004;350:1081-92.
46. Mah V, Seligson DB, Li A, Marquez DC, Wistuba II, Eishimali Y, et al. Aromatase expression predicts survival in women with early-stage non-small cell lung cancer. Cancer Res 2007;67:10484-90.
47. Verma MK, Miki Y, Abe K, Suzuki T, Niikawa H, Suzuki S, et al. Intratumoral localization and activity of 17beta-hydroxysteroid dehydrogenase type 1 in non-small cell lung cancer: a potent prognostic factor. J Transl Med 2013;11:167.
48. Su JM, Hsu HK, Chang H, Lin SL, Chang HC, Huang MS, et al. Expression of estrogen and progesterone receptors in non-small-cell lung cancer: immunohistochemical study. Anticancer Res 1996;16: 3803-6.
49. Kaiser U, Hofmann J, Schilli M, Wegmann B, Klotz U, Wedel S, et al. Steroid-hormone receptors in cell lines and tumor biopsies of human lung cancer. Int J Cancer 1996;67:357-64.
50. Di Nunno L, Larsson LG, Rinehart JJ, Beissner RS. Estrogen and progesterone receptors in non-small cell lung cancer in 248 consecutive patients who underwent surgical resection. Arch Pathol Lab Med 2000;124:1467-70.
51. Raso MG, Behrens C, Herynk MH, Liu S, Prudkin L, Ozburn NC, et al. Immunohistochemical expression of estrogen and progesterone receptors identifies a subset of NSCLCs and correlates with EGFR mutation. Clin Can Res 2009;15:5359-68.
52. Ishibashi H, Suzuki T, Suzuki S, Niikawa H, Lu L, Miki Y, et al. Progesterone receptor in non-small cell lung cancer-a potent prognostic factor and possible target for endocrine therapy. Cancer Res 2005;65:6450-8.
53. Abe K, Miki Y, Ono K, Mori M, Kakinuma H, Kou Y, et al. Highly concordant coexpression of aromatase and estrogen receptor beta in non-small cell lung cancer. Hum Pathol 2010;41:190-8.
54. Xie M, You S, Chen Q, Chen X, Hu C. Progesterone inhibits the migration and invasion of A549 lung cancer cells through membrane progesterone receptor a-mediated mechanisms. Oncol Rep 2013;29: 1873-80.
55. Lange CA, Shen T, Horwitz KB. Phosphorylation of human progesterone receptors at serine-294 by mitogen-activated protein kinase signals their degradation by the 26S proteasome. Proc Natl Acad SciU S A 2000;97:1032-7.
56. Cui X, Lazard Z, Zhang P, Hopp TA, Lee AV. Progesterone crosstalks with insulin-like growth factor signaling in breast cancer cells via induction of insulin receptor substrate-2. Oncogene 2003;22:6937-41.
57. Sutton G. Hormonal aspects of endometrial cancer. Curr Opin Obstet Gynecol 1990;2:69-73.
58. Kelley RM, Baker WH. Progestational agents in the treatment of carcinoma of the endometrium. N Engl J Med 1961;264:216-22.
59. Albain KS, Crowley JJ, LeBlanc M, Livingston RB. Survival determinants in extensive-stage non-small-cell lung cancer: the Southwest Oncology Group experience. J Clin Oncol 1991;9:1618-26.
60. Moore KA, Mery CM, Jaklitsch MT, Estocin AP, Bueno R, Swanson SJ, et al. Menopausal effects on presentation, treatment, and survival of women with non-small cell lung cancer. Ann Thorac Surg 2003;766: 1789-95.
61. Wakelee HA, Dahlberg SE, Schiller JA, Langer CJ, Sandler AB, Brahmer JR, et al. Menopausal status of women may affect survival in advanced NSCLC: analysis of recent Eastern Cooperate Oncology Group (ECOG) studies using age of 60 years or older as a surrogate marker: P1-052. J Thoracic Oncol 2007b;2:S570.
62. Ganti AK, Sahmoun AE, Panwalkar AW, Tendulkar KK, Potti A. Hormone replacement therapy is associated with decreased survival in women with lung cancer. J Clin Oncol 2006;24:59-63
63. Chlebowski RT, Schwartz AG, Wakelee H, Anderson GL, Stefanick ML, Manson JE, et al. Estrogen plus progestin and lung cancer in postmenopausal women. Lancet 2009;375:1243-51.
64. Bouchardy C, Benhamou S, Schaffar R, Verkooijen HM, Fioretta G, Schubert H, et al. Lung cancer mortality risk among breast cancer patients treated with anti-estrogens. Cancer 2011;117:1288-95.
65. Lother SA, Harding GA, Musto G, Navaratnam S, Pitz MW. Antiestrogen use and survival of women with non-small cell lung cancer in Manitoba, Canada. Horm Cancer 2013;4:270-76.
66. Spyridopoulos I, Sullivan AB, Kearney M, Isner JM, Losordo DW. Estrogen-receptor-mediated inhibition of human endothelial cell apoptosis. Circulation 1997;95:1505-14.
67. Xu L, Gao G, Ren J, Su F, Weihua Z. Estrogen receptor b of host promotes the progression of lung cancer brain metastasis of an orthotopic mouse model. J. Cancer Ther 2012;3:352-8.
68. Grott M, Karayaka S, Mayer F, Baertling F, Beyer C, Kipp M, et al. Progesterone and estrogen prevent cisplatin-induced apoptosis of lung cancer cells. Anticancer Res 2013;33:791-800.
69. Slatore CG, Chien JW, Au DH, Satia JA, White E. Lung cancer and hormone replacement therapy: association in the vitamins and lifestyle study. J Clin Oncol 2010;28:1540-6.
70. Clauge J, Reynolds P, Sullivan-Halley J, MaH, Lacey JV Jr, Henderson KD, et al. Menopausal hormone therapy does not influence lung cancer risk: results from the California teachers study. Cancer Epidemiol Biomarkers Prev 2011;20:560-4.
71. Schabath MB,WuX, Vassilopoulou-Sellin R, Vaporciyan AA, Spitz MR. Hormone replacement therapy and lung cancer risk: a case-control analysis. Clin Cancer Res 2004;10:113-23.
72. Schwartz AG, Wenzlaff AS, Prysak GM, Murphy V, Cote ML, Brooks SC, et al. Reproductive factors, hormone use, estrogen receptor expression and risk of non-small cell lung cancer in women. J Clin Oncol 2007;25:5785-92.
73. Pestori AC, Carugno M, Conconni D, Hung RJ, Papadoupolos A, Landi MT, et al. Hormone use and risk for lung cancer: a pooled analysis from the International Lung Cancer Consotrium (ILCCO). Br J Cancer 2013;109:1954-64.
74. Cutolo M, Capellino S, Straub RH. Oestrogens in rheumatic diseases: friend or foe? Rheumatology 2008;47:iii2-5.
75. Nose N, Sugio K, Oyama T, Nozoe T, Uramoto H, Iwata T, et al. Association between estrogen receptor-beta expression and epidermal growth factor receptor mutation in the postoperative prognosis of adenocarcinoma of the lung. J Clin Oncol 2009;27:411-7.
76. Yang SH, Mechanic LE, Yang P, Landi MT, Bowman ED, Wampfler J, et al. Mutations in the tyrosine kinase domain of the epidermal growth factor receptor in non-small cell lung cancer. Clin Cancer Res 2005; 11:2106-10.
77. Traynor AM, Schiller JH, Stabile LP, Kolesar JM, Eickhoff JC, Dacic S, et al. Pilot study of gefitinib and fulvestrant in the treatment of postmenopausal women with advanced non-small cell lung cancer. Lung Cancer 2009;64:51-9.
78. Garon EB, Siegfried JM, Dubinett SM, et al. Results of TORI-L-03, a randomized, multicenter phase II clinical trial of erlotinib (E) or E +fulvestrant (F) in previously treated advanced non-small cell lung cancer (NSCLC). In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington DC. Philadelphia (PA): AACR; 2013. Abstract nr 4664.
79. Okubo S, Kurebayashi J, Otsuki T, Yamamoto Y, Tanaka K, Sonoo H. Additive antitumour effect of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib (Iressa, ZD1839) and the antiestrogen fulvestrant (Faslodex, ICI 182,780) in breast cancer cells. Br J Cancer 2004;901:236-44.
80. Hammoud Z, Tan B, Badve S, Bigsby RM. Estrogen promotes tumor progression in a genetically defined mouse model of lung adenocarcinoma. Endocr Relat Cancer 2008;15:475-83.